Entyvio for GVHS – pro
GvHD after allogeneic bone marrow transplantation is associated with poor outcome and high mortality. Steroids are first line treatment. Vedolizumab, a monoclonal antibody targeting the homing of T cells to the intestinal endothelium through inhibition of the binding of integrin a4b7 to MadCAM, is effective in the treatment of inflammatory bowel disease. It is FDA approved for Crohn’s Diseae and Ulceratie Colitis. Evidence of its activity for GVHD is based on case reports and series. There is, therefore, insufficient evidence to support its use.
K. Lundinn, P-067 Vedolizumab in Treatment of Severe Intestinal Graft Versus Host Disease. Article (PDF Available) in Inflammatory Bowel Diseases 22:S30-S31 · March 2016
Fløisand, Yngvar et al.Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation , Volume 23 , Issue 1 , 172 – 175
Entyvio, Prescribing Information 2019